Resmed (RMD) EBIT Margin (2009 - 2026)

Resmed's EBIT Margin history runs 18 years deep, the most recent figure standing at 34.92% for Q1 2026.

• Quarterly EBIT Margin rose 192.0% year-over-year to 34.92% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.18% (up 207.0% YoY) and the FY2025 annual result came in at 32.75%, up 458.0% from the prior year.
• EBIT Margin was 34.92% for Q1 2026 at Resmed, up from 34.56% in the prior quarter.
• Across five years, EBIT Margin topped out at 34.92% in Q1 2026 and bottomed at 23.66% in Q4 2023.
• A 5-year average of 29.93% and a median of 31.17% in 2024 frame the typical range for EBIT Margin.
• Annual changes were most pronounced in 2023 — EBIT Margin sank 345 bps — and 2024, when it soared 889 bps.
• Resmed's EBIT Margin stood at 27.1% in 2022, then fell by 13 bps to 23.66% in 2023, then surged by 38 bps to 32.54% in 2024, then grew by 6 bps to 34.56% in 2025, then rose by 1 bps to 34.92% in 2026.
• Business Quant data shows RMD's EBIT Margin at 34.92% in Q1 2026, 34.56% in Q4 2025, and 33.43% in Q3 2025.